Dianthus Therapeutics (DNTH) had its price target raised by Guggenheim from $100.00 to $200.00. They now have a "buy" rating on the stock.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]